Serum miR-22 is a novel prognostic marker for acute myeloid leukemia
Open Access
- 1 September 2020
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 34 (9), e23370
- https://doi.org/10.1002/jcla.23370
Abstract
Background It has been demonstrated that aberrant expression of serum microRNAs is potential markers for the prognostic prediction of acute myeloid leukemia (AML). However, the clinical significance of serum miR-22 remained uncovered. In this study, we aimed to explore the potential prognostic value of serum miR-22 for AML. Methods Blood samples were collected from 124 patients with AML and 60 healthy individuals. Serum miR-22 level was detected by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and its potential clinical value was investigated. Results Our results showed that serum miR-22 expression was significantly downregulated in AML subjects compared to healthy controls. Serum miR-22 levels were lowest in AML patients with M4/M5 subtypes, and low serum miR-22 expression occurred more frequently in AML patients with higher white blood cell counts or poor cytogenetic risk. Receiver operating characteristic (ROC) analysis revealed that serum miR-22 well differentiated AML cases from healthy controls. In addition, serum miR-22 downregulation was closely associated with worse clinical features and shorter survival. Low serum miR-22 expression was confirmed to be an independent predictor for overall survival and relapse-free survival in AML patients. Moreover, the expression level of serum miR-22 was dramatically increased following treatment. In addition, serum miR-22 levels were significantly higher in AML patients achieving complete remission (CR) than those without CR. Conclusion Collectively, serum miR-22 might serve as a novel and promising prognostic biomarker for AML.Funding Information
- None
This publication has 25 references indexed in Scilit:
- Role of microRNAs in maintaining cancer stem cellsAdvanced Drug Delivery Reviews, 2014
- Down-regulated miR-22 as predictive biomarkers for prognosis of epithelial ovarian cancer.Diagnostic Pathology, 2014
- Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosisDiagnostic Pathology, 2013
- Acute myeloid leukemia: 2013 update on risk‐stratification and managementAmerican Journal of Hematology, 2013
- Acute myeloid leukaemia in adultsThe Lancet, 2013
- Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)Methods, 2010
- Molecular prognostic markers for adult acute myeloid leukemia with normal cytogeneticsJournal of Hematology & Oncology, 2009
- Treatment of acute myeloid leukemiaHaematologica, 2009
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences of the United States of America, 2008
- Drug therapy for acute myeloid leukemiaBlood, 2005